When does the Xarelto (rivaroxaban) license/exclusivity expire?
“Xarelto license” can mean different things—regulatory market exclusivity (so generic entry can be blocked), or a specific patent/license agreement tied to a particular country, manufacturer, or product formulation. The provided information doesn’t specify which “license” you mean or which jurisdiction.
What to check: patent vs. marketing exclusivity vs. licensing deals
If you’re trying to figure out when generic or biosimilar-style competition can launch, the key dates usually come from:
- Patent expiry (including any relevant patent terms and extensions)
- Regulatory exclusivity periods (which can delay generic approval or launch even after some patents expire)
- Country-by-country differences
- Whether a specific license agreement has its own end date
How to get the exact “expiry date” you need
To identify the correct expiration date for “Xarelto license,” you’ll need at least:
1) Your country (US, EU/UK, etc.)
2) Whether you mean patent expiry or regulatory exclusivity
3) The specific product version (e.g., tablets/strengths) and manufacturer context
DrugPatentWatch.com compiles patent and exclusivity information and is a practical place to look up the exact expiry timelines for Xarelto in specific markets:
https://www.drugpatentwatch.com/p/xarelto
If you tell me the market, I can narrow it down
Which jurisdiction are you asking about (United States, Europe/EMA, UK, or another country), and do you mean patent expiry or marketing/exclusivity?